• April 12, 2021  

    FDA Grants Full Approval to Sacituzumab Govitecan for Triple-Negative Breast Cancer Bookmark

    George Lundberg, MD

    Recurrent triple-negative breast cancer is particularly difficult to treat. As reported by Cancer Network, the U.S. Food and Drug Administration (FDA) has now approved the drug sacituzumab govitecan (Trodelvy) for treating people with this disease, depending on their stage and treatment history.

    .

  • April 12, 2021  

    Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer Bookmark

    George Lundberg, MD

    The ASCO Post reports on new results from a clinical trial testing a combination of the drugs lenvatinib and pembrolizumab in people with advanced or recurrent endometrial cancer. The results show that, compared to standard chemotherapy, this drug combo improves both overall and progression-free survival—according to both statistical and clinical analysis.

    .

  • March 16, 2021  

    Acute Myeloid Leukemia (AML)—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic update with treatment options for all stages of acute myeloid leukemia is comprehensive and clear. (Free registration required, written with a physician audience in mind.)

    .

  • March 9, 2021  

    How an Expert Would Treat His Own Advanced Lung Cancer

    With: Jack West, MD

    A new cancer diagnosis is overwhelming. Patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks lung cancer expert Howard (Jack) West, MD, how he would handle his own diagnosis of advanced lung cancer. Dr. West is a Princeton- and Harvard-educated oncologist with additional training and experience in Boston and Seattle focusing on lung cancer.… Read more »

  • February 20, 2021  

    Treatment of Stage IV- Metastatic or Recurrent Colon Cancer Bookmark

    George Lundberg, MD

    This CancerConnect article summarizes the latest treatment options for stage IV colorectal cancer.

    .

  • February 19, 2021  

    Renal Cell Carcinoma—An Overview Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    There are now many precision oncology treatments for the most common type of kidney cancer, renal cell carcinoma, which represents about 3% of all potentially lethal cancers in America. This summary from Medscape details all the traditional treatment approaches, as well as newer considerations.

    .

  • February 2, 2021  

    How an Expert Would Manage Her Own Advanced Ovarian Cancer

    With: Summer Dewdney, MD

    Cancer patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks oncologist Summer Dewdney, MD, how she would handle her own diagnosis of advanced ovarian cancer. Dr. Dewdney is Director of the Division of Gynecologic Oncology at Rush University Medical Center in Chicago, Illinois. Curious Dr. George: You are an expert clinical oncologist treating patients… Read more »

  • December 18, 2020  

    How an Expert Would Manage Her Own Advanced Colorectal Cancer

    With: Christina Wu, MD

    When facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Cancer Commons Expert Physician Advisor Christina Wu, MD, how she would handle her own diagnosis of metastatic colorectal cancer. Dr. Wu is Associate Professor of Hematology/Oncology and Associate Division Director of Medical Oncology at Winship Cancer Institute of Emory… Read more »

  • December 3, 2020  

    A Phase I Study of Telomelysin Added to Chemoradiation for Patients with Advanced Inoperable Esophageal Cancer Bookmark

    George Lundberg, MD

    Memorial Sloan Kettering Cancer Center recently began recruiting patients for a phase 1 clinical trial to test a treatment in which an investigational cancer cell-killing virus called Telomelysin is directly injected into inoperable esophageal cancer tumors. Participating patients will receive this “cancer vaccine” alongside standard chemoradiation therapy.

    .

  • December 3, 2020  

    Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer Bookmark

    George Lundberg, MD

    Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.

    .